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CASE REPORT
Case Report: Pheochromocytoma Presenting with Cushing’s 
Syndrome and Hyperglycemia
Elizabeth Garbitelli1, Halla Bates1, Cheryl Liechty, MD, MPH2, Robert Bing-You, MD, MEd, MBA3
1Tufts University School of Medicine, Boston, MA, 2 Pen Bay Medical Center, Rockport, ME, 3 Maine Medical Center, 
Portland, ME
Introduction:  Pheochromocytomas are catecholamine-producing neuroendocrine tumors that arise from the adrenal 
medulla. Pheochromocytomas typically present with uncontrollable or paroxysmal hypertension that 
can be accompanied by other common initial symptoms, including headache, diaphoresis, arrhythmia, 
and pallor. Given the morbidity and mortality associated with undiagnosed pheochromocytomas, 
and their potential for treatment, primary care physicians should consider this tumor type, and other 
endocrinological phenomena, when evaluating new onset hyperglycemia.
Clinical Findings:  Patient G was a 76-year-old female who presented in her primary care office with newly uncontrollable 
hyperglycemia. During initial evaluation, her clinical condition deteriorated rapidly. Her laboratory studies 
revealed markedly elevated cortisol, adrenocorticotropic hormone (ACTH), and urine metanephrines. 
Imaging revealed a 3-cm left adrenal mass. Evaluation of ACTH and cortisol levels became complicated 
by discovery of a lung mass.
Clinical Course:  Left adrenalectomy led to resolution of hyperglycemia, catecholamine excess, and Cushing’s Syndrome. 
Tissue pathology of the pheochromocytoma identified ACTH receptor positivity.
Conclusions:  Pheochromocytoma is a rare but possible cause of Cushing’s Syndrome. Patient G’s resolution of 
hypercortisolemia after successful resection of the pheochromocytoma indicate the tumor’s role in 
her hyperglycemia and Cushing’s Syndrome. Despite the well-known association of uncontrollable 
or paroxysmal hypertension with pheochromocytoma, presenting symptoms vary significantly among 
patients. The heterogeneity of this neoplasm’s presentation highlights the role primary care can play in 
building this rare diagnosis into the differential early in the disease course.
Keywords:  pheochromocytoma, Cushing’s Syndrome, hyperglycemia, case report
Patient G was a 76-year-old non-obese female with a medical history of type II diabetes mellitus and breast cancer in remission. In 
the year before presentation, she had normotensive 
blood pressure and did not report headaches, 
sweating, or palpitations. In July 2020, she reported 
severe hyperglycemia, although her blood pressure 
remained normotensive in initial visits. A laboratory 
work-up was initiated (Table 1). The patient also 
reported insomnia, fatigue, and weight loss. Her 
primary care physician ordered a computerized 
tomography (CT) scan of the abdomen and pelvis 
due to concerns for underlying malignancy based 
on leukocytosis. The scan showed a left adrenal 
mass measuring 3.7 x 3.2 cm. Given the CT results, 
Patient G’s physician ordered additional endocrine 
labs. Patient G had high ACTH levels, prompting 
evaluation with a CT scan of the chest, which showed 
a 2.5-cm spiculated mass in the lung. Her severe 
hyperglycemia continued into August, requiring 
emergency department visits, despite metformin 
and sliding-scale insulin therapy. Readings also 
indicated hypertensive blood pressure. Systolic 
pressure readings remained under 190 mmHg, 
and diastolic pressures remained under 100 
mmHg. Guidelines by the International Society 
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Table 1. Select Laboratory Testing Performed Between July 2020 and August 2020
Test Reference range Result
Hemoglobin A1c 4.5%-5.7% 7.2%
Average blood glucose 70-99 mg/dL 311 mg/dL
Thyroid-stimulating hormone 0.270-4.200 uIU/mL 0.231 uIU/L
Free thyroxine 0.90-1.70 ng/dL 0.88 ng/dL
Cortisol (post-dexamethasone 1 mg overnight) 0.0-5.0 ug/dL 118 ug/dL
Cortisol (morning) 6.0-18.4 ug/d 128 ug/dL
Normetanephrine, plasma free <0.90 nmol/L 6.2 nmol/L
Metanephrine, plasma free <0.50 nmol/L 2.5 nmol/L
Adrenocorticotropic hormone (morning) 7.2-63 pg/mL 368 pg/mL
Urine (24 hour)
  Catecholamine, norepinephrine 15-80 mcg 917 mcg
  Catecholamine, epinephrine <21 mcg 248 mcg
  Metanephrine 21-153 mcg/g 4095 mcg
  Normetanephrine 108-524 mcg/g 3920 mcg
  Norepinephrine 7-85 mcg/g 1881 mcg
  Epinephrine 2-16 mcg/g 552 mcg
  Dopamine 40-390 mcg/g 183 mcg
Table 2. Select Post-Operative Laboratory Testing from October 2020
Test Reference range Result
Adrenocorticotropic hormone (morning) 7.2-63 pg/mL 9.3 pg/mL
Cortisol (morning) 6.0-18.4 ug/dL 16.0 ug/dL
Hemoglobin A1c 4.5%-5.7% 6.0%
Normetanephrine, plasma free <0.90 nmol/L 0.92 nmol/L
Metanephrine, plasma free <0.50 nmol/L <0.20 nmol/L
Based on her severe weakness and altered mental 
status, Patient G was transferred to XYZ Hospital 
for her increasingly complex condition in mid-
August 2020. Her lab tests showed hypokalemia, 
elevated liver enzymes, and leukocytosis. A 
metaiodobenzylguanidine scan located the 
previously identified left adrenal mass.
During her hospital stay, Patient G underwent a left 
adrenalectomy that extracted a pheochromocytoma 
of approximately 3 cm. The tumor displayed “patchy 
positivity” for ACTH and “marked diffuse adrenal 
cortical hyperplasia, consistent with ectopic ACTH 
production.” Patient G was discharged to outpatient 
rehabilitation. Post-operatively, her serum cortisol 
and ACTH levels normalized. Her glucose control 
improved with elimination of insulin (Table 2). 
Her blood pressure stabilized and altered mental 
status resolved. The lung mass raised concerns for 
paraneoplastic syndrome versus a post-infectious 
infiltration. However, biopsy of the lung lesion in 
December 2020 showed a benign pathology.
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Pheochromocytomas are neuroendocrine tumors 
that arise from chromaffin cells of the adrenal medulla. 
A hallmark of pheochromocytomas is excess 
catecholamine production. Clinical symptoms of 
these tumors include sustained, uncontrollable 
hypertension or paroxysmal hypertension. The 
hypertension phenotype depends on the amount 
and pattern of catecholamine secretion from the 
tumor, which can vary from continuous (causing 
sustained hypertension) to sporadic (causing 
episodic hypertension).2 Catecholamine excess can 
also lead to headaches, diaphoresis, arrhythmia, 
and pallor. Pheochromocytomas only account for 
3% of ectopic ACTH Cushing’s Syndrome.3 As such, 
hyperglycemia and other symptoms associated with 
Cushing’s Syndrome are not considered common 
clinical manifestations of pheochromocytoma.4,5
Pheochromocytomas remain an enigmatic diagnosis 
due to the myriad of presenting symptoms and 
the paroxysmal nature of the hypertensive spells. 
Patient G’s presentation of sudden uncontrollable 
hyperglycemia without severe hypertension 
represents an unusual case presentation of an 
already rare tumor type. Pheochromocytomas have 
incidence rates as low as 0.8 per 100 000 person-
years.6 However, these tumors can be lethal if 
untreated due to catecholamine crises leading to 
fatal arrhythmias, stroke, and heart failure.7
Even with the pathognomonic presentation of 
episodic hypertensive spells, pheochromocytomas 
are notorious for their elusive and capricious 
presentations. Some research notes that these 
tumors can be asymptomatic for years and 
masquerade behind nonspecific symptoms, such 
as nausea, vomiting, and mildly elevated blood 
glucose.8
A review of the literature revealed up to 78 
case studies describing ACTH-producing 
pheochromocytomas.9,10,11 One of those reports 
showed 10% ACTH receptor positivity in the 
pheochromocytoma pathology, which is consistent 
with our patient’s patchy receptor positivity.11
Diagnosis of a pheochromocytoma typically relies 
on quantifying catecholamine excess by measuring 
the metabolite metanephrines, with an identifiable 
tumor on imaging. For Patient G, an adrenal 
tumor was quickly identified by CT imaging, which 
prompted assessment of metanephrines. However, 
evaluation of metanephrines, ACTH, and cortisol 
levels became complicated by the lung mass 
identified during initial work-up. Considerations 
included small-cell lung carcinoma and bronchial 
carcinoid, requiring further work-up with eventual 
biopsy. Approximately 25% of ectopic ACTH 
Cushing’s Syndrome is associated with bronchial 
carcinoid tumor types.3 Bronchial carcinoid tumors 
resist feedback inhibition, which is tested during the 
high-dose dexamethasone suppression test. Small 
bronchial carcinoid tumors may mimic pulmonary 
vasculature in appearance, indicating that even 
minor imaging findings should be evaluated.12 
Ectopic ACTH from a lung mass would be a 
more likely diagnosis in Patient G’s age group. 
US data indicate the annual incidence of lung 
neuroendocrine masses is approximately 1.49 per 
100 000 persons.13
Patient G’s medical team resected the adrenal 
mass due to the risks of catecholamine excess. This 
resection led to a swift remission of her symptoms. 
Her serum cortisol and ACTH levels normalized 
within a month post-operatively. Her glucose 
control improved with elimination of insulin, her 
blood pressure stabilized, and her altered mental 
status resolved. Imaging showed the persistence 
of the lung lesion prompting further evaluation. CT-
guided biopsy of the lung lesion was conducted in 
December 2020 and showed benign pathology.
Pheochromocytoma is an exceedingly rare but 
possible cause of Cushing’s Syndrome. Patient 
G’s resolution of hypercortisolemia, as well as 
ACTH receptor positivity of pheochromocytoma, 
indicate the tumor’s role in Patient G’s presenting 
hyperglycemia and Cushing’s Syndrome. Case 
presentations such as this one highlight the diversity 
of this group of neoplasms and point toward the 
importance of prompt, thorough evaluation and 
intervention to minimize morbidity and mortality. 
Additionally, this case displays the heterogeneity of 
clinical problems that appear in primary care and 
emphasizes the importance of thorough evaluation 
by primary care providers. Perhaps one of the 
most important first steps in evaluating Patient G 
was considering pheochromocytoma in the original 
differential diagnosis by her primary care physician. 
This diagnostic objectivity allowed Patient G’s 
clinical team to recognize and interpret her unusual 
presentation and promptly begin treatment, leading 
to a near complete resolution of her symptoms.
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